☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
BREEZE-AD1
Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermati...
February 5, 2019
Eli Lilly's Olumiant (baricitinib) Receives FDA's Fast Track Designation for Systemic Lupus Erythematosus (SLE)
December 14, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.